Latest news with #OKYOPharma
Yahoo
21-07-2025
- Business
- Yahoo
OKYO reports top-line data from neuropathic corneal pain therapy trial
OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod (previously referred to as OK-101), aimed at treating neuropathic corneal pain (NCP). The double-masked, placebo-controlled trial was carried out at Tufts Medical Center in Boston, US, with Pedram Hamrah as the principal investigator. Its primary endpoint was the change in mean pain scores from baseline to the end of the 12-week treatment period, measured using Visual Analogue Scale (VAS) scores of zero to ten. The company noted that, for the per-protocol population, the 0.05% urcosimod group showed a mean pain score change of 5.5 while the placebo group had a change of 2.75, indicating a 2.75 delta difference between the drug and the placebo after 12 weeks of treatment. In addition, 75% of subjects treated with 0.05% urcosimod achieved an improvement in pain severity of over 80%. The 0.05% therapy showed a marked decrease in pain scores as early as week four, with a mean change of 5.25, compared with 3.0 for the placebo. Although the placebo group also saw improvement, it was notably less than that of the urcosimod group, and 75% of those subjects had only mild NCP pain scores at baseline. In the intent-to-treat subjects, 67% of those in the 0.05% group showed an improvement of more than 50% in pain, versus 33% in the placebo group. The mean decrease in pain severity was 4.2 for the 0.05% therapy group, versus 2.5 for the placebo group. A Cohen-d value of greater than 1.2 indicated a strong treatment impact. Cohen-d is a statistical metric used to evaluate and contrast the effect size of the trial medication with that of the placebo. NCP causes intense pain and sensitivity in the eyes, as well as the face and head. The company noted that the Phase II trial of urcosimod was planned to enrol 48 subjects, but OKYO Pharma closed the trial early in April this year. With 17 subjects having completed the trial, the decision was based on the company's aim to unmask the data for an early readout on the drug's impact. OKYO Pharma CEO Gary Jacob said: 'We are thrilled with these initial top-line results in patients treated with urcosimod from this first in-human Phase II trial. 'In particular, the results strengthen our conviction that this drug may be particularly effective at showing a significant reduction in pain in patients with a greater degree of neuropathic pain.' In 2023, OKYO screened the first subject in its Phase II trial of OK-101 ophthalmic solution to treat dry eye disease (DED). "OKYO reports top-line data from neuropathic corneal pain therapy trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
14-06-2025
- Business
- Yahoo
OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders
OKYO Pharma's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 42% of the business is held by the top 12 shareholders Insider ownership in OKYO Pharma is 36% We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. A look at the shareholders of OKYO Pharma Limited (NASDAQ:OKYO) can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 58% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Following a 58% increase in the stock price last week, individual investors profited the most, but insiders who own 36% stock also stood to gain from the increase. Let's take a closer look to see what the different types of shareholders can tell us about OKYO Pharma. View our latest analysis for OKYO Pharma Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. As you can see, institutional investors have a fair amount of stake in OKYO Pharma. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of OKYO Pharma, (below). Of course, keep in mind that there are other factors to consider, too. We note that hedge funds don't have a meaningful investment in OKYO Pharma. Gabriele Marco Cerrone is currently the largest shareholder, with 29% of shares outstanding. For context, the second largest shareholder holds about 6.8% of the shares outstanding, followed by an ownership of 5.9% by the third-largest shareholder. Our studies suggest that the top 12 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our information suggests that insiders maintain a significant holding in OKYO Pharma Limited. Insiders have a US$37m stake in this US$102m business. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently. The general public, who are usually individual investors, hold a substantial 58% stake in OKYO Pharma, suggesting it is a fairly popular stock. This level of ownership gives investors from the wider public some power to sway key policy decisions such as board composition, executive compensation, and the dividend payout ratio. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 4 warning signs we've spotted with OKYO Pharma (including 2 which make us uncomfortable) . If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
